Skip to main content

Table 3 Treatment exposure by history of calcinosis

From: Clinical phenotypes and biologic treatment use in juvenile dermatomyositis-associated calcinosis

Risk factor

Descriptive analysis

  

Univariable analysis

Calcinosis

 

OR [95% CI]

p-value

Yes

No

Biologic treatment (Ever)

n (%)

   

 Any biologic

48 (57.1)

194 (35.5)

0.0001

2.426 [1.522–3.867]

 

 Rituximab

12 (14.3)

14 (2.6)

< 0.0001

6.345 [2.825–14.254]

< 0.001

 IV Immune Globulin

45 (53.6)

180 (32.9)

0.0002

2.353 [1.479–3.743]

0.0003

 Anti-TNF

12 (14.3)

23 (4.2)

0.0009

3.797 [1.812–7.960]

0.0004

 Abatacept

2 (2.4)

1 (0.2)

0.048

13.317 [1.194–148.514]

0.0354

 Anti-IL1

1 (1.2)

1 (0.2)

   

High steroid exposure

47 (56)

269 (54.3)

  Â